Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1099-1103

  Yuen, Man Fung ^a   Wong, Danny Ka Ho ^a   Sum, Simon Siu Man ^a   Yuan, He Jun ^a   Yuen, John Chi Hang ^a   Chan, Annie On On ^a   Wong, Benjamin Chun Yu ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COVALENTLY CLOSED CIRCULAR DNA; LAMIVUDINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARTIC ACID; CIRCULAR DNA; ISOLEUCINE; METHIONINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; VALINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS INHIBITION; VIRUS MUTATION; YMDD GENE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; GENETICS; HEPATITIS B VIRUS; MIDDLE AGED; MUTATION; PROTEIN MOTIF; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADOLESCENT; ADULT; AMINO ACID MOTIFS; ANTI-HIV AGENTS; ASPARTIC ACID; DNA, CIRCULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; ISOLEUCINE; LAMIVUDINE; MALE; METHIONINE; MIDDLE AGED; MUTATION; PLACEBOS; REVERSE TRANSCRIPTASE INHIBITORS; TYROSINE; VALINE; VIRAL LOAD;

EID: 19144371967     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41530.x     Document Type: Article

References (25)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
2. Mason WS, Halpern MS, England JM, et al. Experimental transmission of duck hepatitis B virus. Virology 1983;131:375-84.
3. Tagawa M, Omata M, Okuda K. Appearance of viral RNA transcripts in the early stage of duck hepatitis B virus infection. Virology 1986;152:477-82.
4. Summers J, Smith PM, Horwich AI. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990;64:2819-24.
5. Summers J, Smith PM, Huang MJ, et al. Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. J Virol 1991;65:1310-7.
6. Lenhoff RJ, Luscombe CA, Summers J. Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Virology 1988;251:85-95.
7. Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.
8. Addison WR, Walters KA, Wong WWS, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002;76:6356-63.
9. Liu MC, Yu M, Zhang NL, et al. Dynamic analysis of hepatitis B virus DNA and its antigens in 2.2.15 cells. J Viral Hepat 2004;11:124-9.
10. Wu CH, Ouyang EC, Walton CM, et al. Human hepatocytes transplanted into genetically immunocompetent rats are susceptible to infection by hepatitis B virus in situ. J Viral Hepat 2001;8:111-9.
11. Chen Y, Sze J, He ML. HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol 2004;10:82-5.
12. Wong DKH, Yuen MF, Yuen HJ, et al. Quantification of serum and intrahepatic total hepatitis B virus DNA and covalently closed circular DNA in chronic hepatitis B patients. Hepatology 2004;40:727-37.
13. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
14. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
15. Zhou T, Guo JT, Nunes FA, et al. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol 2000;74:11754-63.
16. Yokosuka O, Omata M, Imazeki F, et al. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985;5:728-34.
17. Lai CL, Yuen MF, Hui CK, et al. A comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy. J Med Virol 2002;67:334-8.
18. Yuen MF, Sablon E, Hui CK, et al. Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 Pt 1):785-91.
19. Stoll-Becker S, Repp R, Gleve D, et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol 1997;71:5399-407.
20. Torii N, Hasegawa K, Job R, et al. Configuration and replication competence of hepatitis B virus DNA in peripheral blood mononuclear cells from chronic hepatitis B patients and patients who have recovered from acute self-limited hepatitis. Hepatol Res 2003;25:234-3.
21. Cabrerizo M, Bartolomé J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000;32:116-23.
22. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-22.
23. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994;42:306-10.
24. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-33.
25. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-45.